{
    "clinical_study": {
        "@rank": "68637", 
        "arm_group": [
            {
                "arm_group_label": "S-1+oxaliplatin", 
                "arm_group_type": "Experimental", 
                "description": "S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles."
            }, 
            {
                "arm_group_label": "S-1+cisplatin", 
                "arm_group_type": "Active Comparator", 
                "description": "S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the efficiency and safety of SOX or SP adjuvant chemotherapy to phase II and\n      III gastric cancer patients after D2 surgery. If SOX is equal to SP in efficiency and less\n      toxicity."
        }, 
        "brief_title": "A Phase\u2161 Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically confirmed Phase III adenocarcinoma of gastric and esophageal-gastric\n             junction ( AJCC 7th)\n\n          -  without previous treatment, including radiotherapy, chemotherapy and immunotherapy\n\n          -  Hb\u226590g/L,WBC 4\u00d7109/L-10\u00d7109/L,ANC\u22652\u00d7109/L,Platelet\u2265100\u00d7109/L\n\n          -  creatinine\u22641 UNL\n\n          -  total bilirubin\u22641.5 UNL,AST(SGOT),ALT(SGPT) and ALP\u22642.5 UNL\n\n          -  ECOG score 0 - 2\n\n          -  take chemotherapy for 8 weeks after surgery\n\n          -  older than 18 years\n\n          -  can be followed up, good compliance\n\n          -  can take medicine orally\n\n          -  having signed informed consent\n\n        Exclusion Criteria:\n\n          -  combined disease lead to Life Expectancy less than 3 years\n\n          -  any evidence to show metastasis,including cancer cells in peritoneal fluid\n\n          -  inability to take oral medication for difficult to swallow, intestinal\n             obstruction\uff0cactive intestinal blooding or perforation\n\n          -  previous treatment,including cytotoxic chemotherapy, radio chemotherapy or\n             immunotherapy ( except corticosteroid hormone\uff09\n\n          -  operation within 4 weeks, or not recovered from last major operation\n\n          -  allergy with fluorouracil\n\n          -  allergy with Platinum or any  composition in research drugs\n\n          -  uncontrollable seizure disorder\uff0ccentral nervous system disease or mental disorders,\n             and has clinical significance by judgement of researchers, or can influnce\n             understanding of informed consent or compliance to take orally drugs\n\n          -  in the past 12 months, has clinical significant heart disease(active),such as\n             symptomatic coronary heart disease, > =Stage II congestive cardiac failure;congestive\n             heart failure as NYHA standard, or serious  arrhythmias need take medicine( as\n             Appendix 10th),or myocardical infarction.\n\n          -  pregnancy\uff0c lactation\uff0c women in child-bearing period and her spouses reject to take\n             effictive method to conraception\n\n          -  other previous malignancy within 5 years, except healed skin basal cell carcinoma and\n             carcinoma in cervix\n\n          -  peripheral neuropathy> grade 1 of CTCAEv3, except the neural abnormality patients who\n             only lose deep tendon reflex\uff08DTRs\uff09.\n\n          -  serious complicated infection or other complicated diseases and hard to controll.\n\n          -  As one of belowing:\n\n          -  ANC  < 2\u00d7109/L\n\n          -  Platelet<100\u00d7109/L\n\n          -  total bilirubin>1.5 UNL\n\n          -  ALAT\u3001ASAT > 2.5 x ULN\n\n          -  ALP> 2.5 x ULN\n\n          -  Any investigational agent within the past 28 days. That is the patient had jioned\n             another trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679340", 
            "org_study_id": "SOXSP"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "S-1+oxaliplatin", 
                    "S-1+cisplatin"
                ], 
                "description": "Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles", 
                "intervention_name": "S-1", 
                "intervention_type": "Drug", 
                "other_name": [
                    "TS-1", 
                    "Aisiwan"
                ]
            }, 
            {
                "arm_group_label": "S-1+oxaliplatin", 
                "description": "Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles", 
                "intervention_name": "oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "S-1+cisplatin", 
                "description": "Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastric cancer", 
            "D2 surgery", 
            "S-1", 
            "Oxaliplatin", 
            "cisplatin"
        ], 
        "lastchanged_date": "September 2, 2012", 
        "location": {
            "contact": {
                "email": "xiaotong10241@sina.com", 
                "last_name": "Shen Lin, Professor", 
                "phone": "010-88196561"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Bejing", 
                    "zip": "100142"
                }, 
                "name": "Beijing Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "Shen Lin, professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase \u2161 Study of S-1 Combined With Oxaliplatin (SOX)Verse S-1 Combined With Cisplatin(SP) in Adjuvant Chemotherapy After D2 Surgery", 
        "overall_contact": {
            "email": "xiaotong10241@sina.com", 
            "last_name": "Shen Lin, professor", 
            "phone": "010-88196561"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "replase free survival", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679340"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Shen Lin", 
            "investigator_title": "Director of GI oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Peking University", 
        "sponsors": {
            "collaborator": {
                "agency": "Taiho Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}